Sara Arciniegas Ruiz

Dr. Sara Arciniegas Ruiz

Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
DSDanna Sheinboim
Danna Sheinboim
SPShivang Parikh
Shivang Parikh
PMPaulee Manich
Paulee Manich
IMIrit Markus
Irit Markus
SDSapir Dahan
Sapir Dahan
CLCarmit Levy
Carmit Levy
Exercise prevents cancer incidence and recurrence, yet the underlying mechanism behind this relationship remains mostly unknown. Here we report that exercise induces the metabolic reprogramming of internal organs that increases nutrient demand and protects against metastatic colonization by limiting nutrient availability to the tumor, generating an exercise-induced metabolic shield. Proteomic and ex vivo metabolic capacity analyses of murine internal organs revealed that exercise induces catabolic processes, glucose uptake, mitochondrial activity, and GLUT expression. Proteomic analysis of routinely active human subject plasma demonstrated increased carbohydrate utilization following exercise. Epidemiologic data from a 20-year prospective study of a large human cohort of initially cancer-free participants revealed that exercise prior to cancer initiation had a modest impact on cancer incidence in low metastatic stages but significantly reduced the likelihood of highly metastatic cancer. In three models of melanoma in mice, exercise prior to cancer injection significantly protected against metastases in distant organs. The protective effects of exercise were dependent on mTOR activity, and inhibition of the mTOR pathway with rapamycin treatment ex vivo reversed the exercise-induced metabolic shield. Under limited glucose conditions, active stroma consumed significantly more glucose at the expense of the tumor. Collectively, these data suggest a clash between the metabolic plasticity of cancer and exercise-induced metabolic reprogramming of the stroma, raising an opportunity to block metastasis by challenging the metabolic needs of the tumor. Significance: Exercise protects against cancer progression and metastasis by inducing a high nutrient demand in internal organs, indicating that reducing nutrient availability to tumor cells represents a potential strategy to prevent metastasis. See related commentary by Zerhouni and Piskounova, p. 4124

Verified
Journal Article
Open access
PDF file
IRIdo Rippin
Ido Rippin
NKNetaly Khazanov
Netaly Khazanov
SJShirley Ben Joseph
Shirley Ben Joseph
TKTania Kudinov
Tania Kudinov
EBEva Berent
Eva Berent
Hagit Eldar-FinkelmanHagit Eldar-Finkelman
Hagit Eldar-Finkelman
The serine/threonine kinase, GSK-3, is a promising drug discovery target for treating multiple pathological disorders. Most GSK-3 inhibitors that were developed function as ATP competitive inhibitors, with typical limitations in specificity, safety and drug-induced resistance. In contrast, substrate competitive inhibitors (SCIs), are considered highly selective, and more suitable for clinical practice. The development of SCIs has been largely neglected in the past because the ambiguous, undefined nature of the substrate-binding site makes them difficult to design. In this study, we used our previously described structural models of GSK-3 bound to SCI peptides, to design a pharmacophore model and to virtually screen the “drug-like” Zinc database (~6.3 million compounds). We identified leading hits that interact with critical binding elements in the GSK-3 substrate binding site and are chemically distinct from known GSK-3 inhibitors. Accordingly, novel GSK-3 SCI compounds were designed and synthesized with IC50 values of~1–4 μM. Biological activity of the SCI compound was confirmed in cells and in primary neurons that showed increased β-catenin levels and reduced tau phosphorylation in response to compound treatment. We have generated a new type of small molecule GSK-3 inhibitors and propose to use this strategy to further develop SCIs for other protein kinases.

1 January 2023 in AIMS Neuroscience
Verified
Journal Article
Open access
PDF file
SRSara Arciniegas Ruiz
Sara Arciniegas Ruiz
ETEliav Tikochinsky
Eliav Tikochinsky
VRVardit Rubovitch
Vardit Rubovitch
CPChaim G Pick
Chaim G Pick
BABernard Attali
Bernard Attali
Background In the fear memory network, the hippocampus modulates contextual aspects of fear learning while mutual connections between the amygdala and the medial prefrontal cortex are widely involved in fear extinction. G-protein-coupled receptors (GPCRs) are involved in the regulation of fear and anxiety, so the regulation of GPCRs in fear signaling pathways can modulate the mechanisms of fear memory acquisition, consolidation and extinction. Various studies suggested a role of M-type K+ channels in modulating fear expression and extinction, although conflicting data prevented drawing of clear conclusions. In the present work, we examined the impact of M-type K+ channel blockade or activation on contextual fear acquisition and extinction. In addition, regarding the pivotal role of the hippocampus in contextual fear conditioning (CFC) and the involvement of the axon initial segment (AIS) in neuronal plasticity, we investigated whether structural alterations of the AIS in hippocampal neurons occurred during contextual fear memory acquisition and short-time extinction in mice in a behaviorally relevant context. Results When a single systemic injection of the M-channel blocker XE991 (2 mg/kg, IP) was carried out 15 minutes before the foot shock session, fear expression was significantly reduced. Expression of c-Fos was increased following CFC, mostly in GABAergic neurons at day 1 and day 2 post-fear training in CA1 and dentate gyrus hippocampal regions. A significantly longer AIS segment was observed in GABAergic neurons of the CA1 hippocampal region at day 2. Conclusions Our results underscore the role of M-type K + channels in CFC and the importance of hippocampal GABAergic neurons in fear expression.

1 December 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SRSara Arciniegas Ruiz
Sara Arciniegas Ruiz
LOLilia Gutiérrez Olvera
Lilia Gutiérrez Olvera
MBMaría Josefa Bernad Bernad
María Josefa Bernad Bernad
SCSara del Carmen Caballero Chacón
Sara del Carmen Caballero Chacón
DVDinorah Vargas-Estrada
Dinorah Vargas-Estrada

12 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
SRSara Arciniegas Ruiz
Sara Arciniegas Ruiz
IRIdo Rippin
Ido Rippin
Hagit Eldar-FinkelmanHagit Eldar-Finkelman
Hagit Eldar-Finkelman
Over the last decade, there has been continuous progress in our understanding of the biology of the protein kinase GSK-3

1 April 2015 in American Journal of Veterinary Research
Verified
Journal Article
Closed access
SRSara Arciniegas Ruiz
Sara Arciniegas Ruiz
LOLilia Gutiérrez Olvera
Lilia Gutiérrez Olvera
SCSara del Carmen Caballero Chacón
Sara del Carmen Caballero Chacón
DEDinorah Vargas Estrada
Dinorah Vargas Estrada
OBJECTIVE To determine the pharmacokinetics of doxycycline hyclate administered orally in the form of experimental formulations with different proportions of acrylic acid–polymethacrylate-based matrices. ANIMALS 30 healthy adult dogs. PROCEDURES In a crossover study, dogs were randomly assigned (in groups of 10) to receive a single oral dose (20 mg/kg) of doxycycline hyclate without excipients (control) or extended-release formulations (ERFs) containing doxycycline, acrylic acid polymer, and polymethacrylate in the following proportions: 1:0.5:0.0075 (ERF1) or 1:1:0.015 (ERF2). Serum concentrations of doxycycline were determined for pharmacokinetic analysis before and at several intervals after each treatment. RESULTS Following oral administration to the study dogs, each ERF resulted in therapeutic serum doxycycline concentrations for 48 hours, whereas the control treatment resulted in therapeutic serum doxycycline concentrations for only 24 hours. All pharmacokinetic parameters for ERF1 and ERF2 were significantly different; however, findings for ERF1 did not differ significantly from those for the control treatment. CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that both ERFs containing doxycycline, acrylic acid polymer, and polymethacrylate had an adequate pharmacokinetic-pharmacodynamic relationship for a time-dependent drug and a longer release time than doxycycline alone following oral administration in dogs. Given the minimum effective serum doxycycline concentration of 0.26 μg/mL, a dose interval of 48 hours can be achieved for each tested ERF. This minimum inhibitory concentration has the potential to be effective against several susceptible bacteria involved in important infections in dogs. Treatment of dogs with either ERF may have several benefits over treatment with doxycycline alone.